Clinical trial NCT04185558: Safety and Efficacy of ActiGraft Pro Compared to Standard of Care in DFUs
Official title: Multi-Center, Prospective, Randomized, Controlled, Trial, Comparing the Safety and Efficacy of ActiGraft Pro™ to Standard of Care in Patients With Chronic Neuropathic Diabetic Foot Ulcers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Foot
Chronic Ulcer
Lead sponsor: RedDress Ltd.
Sponsor class: INDUSTRY
First posted: 2019-12-04
Enrollment: 119
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * The study is a multi-center, prospective, randomized, controlled, single blinded clinical study consisting of 150 subjects from up to 20 centers.
* The subjects are randomized to receive 1 of 2 treatments, either with ActiGraft and standard of care (SOC) or with SOC alone.
* The target ulcers are evaluated weekly by the investigator. The subject is treated once a week, to receive weekly applications of the ActiGraft + SOC or SOC until for up to 12 weeks or until the study ulcer has completely healed (i.e., 100% closure as assessed by the Investigator and blinded assessor and confirmed 2 weeks later at the healing confirmation visit (HCV). One additional visit per week is optional for both arms, for the purpose of changing only (1) the secondary dressing in the ActiGraft arm or (2) change the standard of care dressing in the control arm.
* Immediately after the study ulcer is confirmed as completely healed, subjects will enter the 12-week Follow-up Phase. During the Follow-Up phase, subjects will be evaluated twice during the first month and then monthly for two additional visits every 4 weeks until the completion of the 12-week Follow-up Phase.


Eligibility criteria: Inclusion Criteria:

* Subject is ≥19 years of age and has type 1 or 2 diabetes
* Chronic neuropathic DFU, located distal to the malleolus (excluding ulcers between the toes but including those of the heel) and depth ≤ 5 mm with no exposed capsule, tendon or bone and no tunneling, undermining or sinus tracts (Minor tunneling and undermining will be included).
* Ulcer size between 1 cm2 and 28 cm2 (post-debridement).
* For subjects with potentially multiple eligible DFUs, the largest non-healing wound will be selected.
* Ulcer duration of ≥ 30 days. Time 0 for ulcer duration of ≥ 30 days is defined as the first day of screening (i.e., day -14). Subjects will need to meet all inclusion criteria, including lack of ulcer healing until randomization day.
* Study ulcer separated from other ulcers by at least 1 cm.
* Ulcer or affected limb free of clinical signs of infection.
* Post-debridement, ulcer free of necrotic tissue.
* Adequate circulation to the affected extremity as demonstrated by at least one of the following: (1) Transcutaneous oxygen test (TcPO2) ≥ 30 mm Hg,; (2) Ankle Brachial Index (ABI) between 0.7 and 1.2; (3)Triphasic or biphasic Doppler arterial waveforms at the ankle of affected leg; (4) Toe Brachial Index \> 0.6
* HbA1c ≤ 12.0%
* Demonstrated adequate offloading regimen.
* Subject must be willing to comply with the protocol including having blood drawn to create the ActiGraft.
* Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study

Exclusion Criteria:

* Ulcer not of neuropathic diabetic foot pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, or arterial etiology, or pressure ulcers.).
* Known or suspected ulcer malignancy of the index ulcer.
* Active Charcot of the affected foot
* Presence of underlying osteomyelitis.
* Subject with a proven sepsis established by a blood culture in the past 2 weeks, or confirmed active infection likely to interfere with trial, such as urine tract infection.
* History of alcohol or substance abuse, within the previous 2 months
* Subject has participated in another clinical trial involving a device or a systemically administered investigational study drug or treatment within 30 days of randomization visit.
* Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive a medication or treatment which, in the opinion of the Investigator, is known to interfere with, or affect the rate and quality of, wound healing (e.g., systemic steroids (more than 10mg per day), immunosuppressive therapy, autoimmune disease therapy, cytostatic therapy within the past 12 months, dialysis, radiation therapy to the foot, planned vascular surgery on the study ulcer limb on the 90 days from screening, angioplasty or thrombolysis, chemotherapy).
* Subject has been treated with wound dressings that include growth factors, engineered tissues or skin substitutes (e.g., Regranex®, Dermagraft®, Apligraf®, GraftJacket®, OASIS®, Primatrix®, Matristem®, etc.) within 30 days of randomization or is scheduled to receive during the study.
* Subject has been treated with hyperbaric oxygen within 5 days of screening or is scheduled to receive during the study.
* Wound on a subject who has a life expectancy of less than 12 months.
* Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the informed consent form.
* Cannot withdraw blood in the required amount (up to 15 mL per week) technically.
* Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Subjects who are taking coumadin, aspirin, Plavix (clopidogrel), Eliquis or Pradaxa will not be excluded.
* Hemoglobin anemia (\< 9 g/dL).
* Subject has a history of or any of the following intercurrent illnesses or conditions that would compromise the safety of the subject, or the normal wound healing process: (1) End stage renal disease; (2)Immunosuppression; (3) Severe malnutrition; (4) Liver disease; (5) Scleroderma; (6) Acquired immune deficiency disease (AIDS) or HIV positive; (7) Active connective tissue disorder; (8)Exacerbation of sickle cell anemia
* If ulcer area decreases by ≥ 30% during the initial 2-week screening (± 2 days) and standard of care phase, subject will be excluded.
* Women who are pregnant or currently breast feeding.

Primary outcomes:
measure: Incidence of complete wound closure by 12 weeks
timeFrame: 12 weeks
Secondary outcomes:
measure: Time to complete wound closure
timeFrame: 12 weeks
measure: Percent area reduction (PAR)
timeFrame: 4 weeks and 8 weeks
measure: Nature, frequency, and severity of adverse events in the intent to treat population
timeFrame: 12 weeks
measure: Number of patients showing a consistence wound closure post healing determination
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Montgomery
country: United States
facility: Institute for Advanced Wound Care
state: Alabama
city: Los Angeles
country: United States
facility: New Hope Podiatry Group Inc
state: California
city: Los Angeles
country: United States
facility: Greater Los Angeles VA
state: California
city: San Francisco
country: United States
facility: Center for Clinical Research Inc
state: California
city: Sylmar
country: United States
facility: Olive View UCLA Education & Research Institute
state: California
city: Coconut Creek
country: United States
facility: Eric J Lullove DPM PA
state: Florida
city: Miami
country: United States
facility: Future Health Research Clinic
state: Florida
city: North Miami Beach
country: United States
facility: Barry University Clinical Research
state: Florida
city: Hilo
country: United States
facility: Pacific Vascular Institute
state: Hawaii
city: Boston
country: United States
facility: Boston Medical Center
state: Massachusetts
city: Las Vegas
country: United States
facility: Wahab Consulting and Research LLC
state: Nevada
city: Philadelphia
country: United States
facility: Temple University
state: Pennsylvania
city: Germiston
country: South Africa
facility: Wound Care South Africa
city: Lyttelton
country: South Africa
facility: Haute Care
city: Tyger Valley
country: South Africa
facility: Eloquent Health & Wellness
city: Istanbul
country: Turkey
facility: Acinadem Altunizade
Study officials:
References: